Brief: Shilpa Medicare, mAbTree Biologics Get FDA Orphan Drug Designation
28/01/2026 09:46
Jan 28 (Reuters) - Shilpa Medicare Ltd SHME.NS: CO AND MABTREE BIOLOGICS RECEIVE FDA ORPHAN DRUG DESIGNATION Source text: ID:nNSEsVkvf Further company coverage: SHME.NS ((Reutersbriefs@thomsonreuters.com;))
Recent news on Shilpa Medicare
See all newsBrief: Shilpa Medicare Q2 Consol Net Profit INR 791.8 Million
Brief: Shilpa Medicare Says USFDA Conducts Surveillance Inspection At Shilpa Medicare Unit
Brief: Shilpa Medicare Receives Final SEC Approval For Oeris Marketing Authorization
India's Shilpa Medicare gains on approval for OERIS
Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026